Atara Biotherapeutics Inc. and Pierre Fabre SA announced the approval of Tabelecleucel, a therapy for a rare and potentially fatal malignancy.
The European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction.
"Solutions for an endangered planet" is what industrial biotechnology seeks and offers. Technical innovations based on nature’s toolbox are intended to help "biologise" industry – in other words, to adapt it to the natural cycles of our planet.
MinervaX inks €72m financing deal with Novo Holdings REPAIR Impact Fund to develop a vaccine against Group B Streptococcus.
A child with recurrent T-cell leukaemia was given base-edited T-cells in a world-first application of a base-edited cell therapy.
According to Bloomberg, the US biotechnology giant Amgen plans to buy Horizon Therapeutics at a valuation of about $26bn. Overall, the deal corresponds to an enterprise value including debt of $28.3bn. This would be the largest acquisition in the company’s history.
Step Pharma intruduces promising data on the potential of a selective cancer treatment by inhibition of CTPS1 with their inhibitor STP938.
The partnering event BioFit2022 took place in Strasbourg, France on November 29th and 30th as well as online on December 7th and 8th. It reflected on challenging times in the pandemic, survivors’ of the economic threats, and adressed the preparation and perseverance needed to deal with challenges today and in the future. The bottom line: dynamic partnerships and more financing opportunities on the horizon.
The European Commission has now recommended concrete steps that, while not yet final, would require Illumina to "swiftly" reverse its controversial $7.1bn acquisition of Grail.
Renewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced that the companies have entered into a research collaboration for several multi-target immunotherapy programmes, as well as an exclusive licensing agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.